Ko Jenny J, Grewal Jasleen K, Ng Tony, Lavoie Jean-Michel, Thibodeau My Linh, Shen Yaoqing, Mungall Andrew J, Taylor Greg, Schrader Kasmintan A, Jones Steven J M, Kollmannsberger Christian, Laskin Janessa, Marra Marco A
Systemic Therapy, BC Cancer - Abbotsford, Abbotsford, British Columbia V2S 0C2, Canada.
Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 4S6, Canada.
Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6). doi: 10.1101/mcs.a003137. Print 2018 Dec.
Thyroid-like follicular renal cell carcinoma (TLFRCC) is a rare cancer with few reports of metastatic disease. Little is known regarding genomic characteristics and therapeutic targets. We present the clinical, pathologic, genomic, and transcriptomic analyses of a case of a 27-yr-old male with TLFRCC who presented initially with bone metastases of unknown primary. Genomic DNA from peripheral blood and metastatic tumor samples were sequenced. A transcriptome of 280 million sequence reads was generated from the same tumor sample. Tumor somatic expression profiles were analyzed to detect aberrant expression. Genomic and transcriptomic data sets were integrated to reveal dysregulation in pathways and identify potential therapeutic targets. Integrative genomic analysis with The Cancer Genome Atlas (TCGA) data set revealed the following outliers in gene expression profiles: (81st percentile), (99th percentile), (100th percentile), and (99th and 100th percentiles, respectively), and (86th percentile). The patient received first-line sunitinib to target PDGFRA and PDGFRB and had stable disease for >6 mo, followed by nivolumab upon progression. To the authors' knowledge, this is the first reported case of comprehensive somatic genomic analyses in a patient with metastatic TLFRCC. Somatic analyses provided molecular confirmation of the primary site of cancer and potential therapeutic strategies in a rare disease with little evidence of efficacy on systemic therapy.
甲状腺样滤泡性肾细胞癌(TLFRCC)是一种罕见癌症,关于其转移性疾病的报道很少。目前对其基因组特征和治疗靶点知之甚少。我们报告了一例27岁男性TLFRCC患者的临床、病理、基因组和转录组分析,该患者最初表现为原发灶不明的骨转移。对来自外周血和转移瘤样本的基因组DNA进行了测序。从同一肿瘤样本中生成了一个包含2.8亿条序列读数的转录组。分析肿瘤体细胞表达谱以检测异常表达。整合基因组和转录组数据集以揭示通路失调并确定潜在治疗靶点。与癌症基因组图谱(TCGA)数据集进行的综合基因组分析揭示了基因表达谱中的以下异常值:(第81百分位数)、(第99百分位数)、(第100百分位数)、以及(分别为第99和第100百分位数),和(第86百分位数)。该患者接受了以PDGFRA和PDGFRB为靶点的一线舒尼替尼治疗,疾病稳定超过6个月,疾病进展后接受纳武单抗治疗。据作者所知,这是首例报道的对转移性TLFRCC患者进行全面体细胞基因组分析的病例。体细胞分析为一种罕见疾病的癌症原发部位提供了分子确认以及潜在治疗策略,而该疾病在全身治疗方面几乎没有疗效证据。